Guide · Updated November 2026

Does FEHB Cover GLP-1 Medications in 2026?

Q: Why do federal employees report such different costs for the same drug?

The OPM mandate requires coverage of at least one GLP-1, but leaves tier placement, cost-sharing, and prior authorization criteria to each carrier and plan, so costs vary significantly across FEHB plans.

Q: What happens to my FEHB GLP-1 coverage when I retire?

We could not confirm a single OPM rule for retirees on a carrier's Medicare Advantage or Part D plan. Ask your carrier for its Medicare-side formulary when you transition.

Every FEHB (Federal Employees Health Benefits) carrier has been required to cover at least one GLP-1 since a [January 2023 Carrier Letter from the Office of Personnel Management](https://www.oversight.gov/sites/default/files/documents/reports/2025-12/2025-CAAG-019.pdf). That requirement is why "does FEHB cover GLP-1s" has a yes answer at the program level. The real question for a federal employee is which plan you're on and what that plan's tier, prior authorization rules, and cost-sharing look like.

Coverage at the program level and coverage at the plan level are different things here, and the gap between them is where most of the confusion and most of the cost difference lives.

FEHB GLP-1 coverage at a glance

Question	Short answer
Does OPM require FEHB carriers to cover a GLP-1?	Yes. OPM issued the requirement in January 2023, and the 2027 call letter keeps it: at least one GLP-1 for weight loss plus at least two oral anti-obesity options
Does that mean my specific plan covers the specific drug my doctor prescribed?	Not necessarily. Which drug, which tier, and what prior authorization applies varies by carrier and plan option
Is GLP-1 coverage easier for diabetes than for weight loss?	Yes, across essentially every FEHB plan
Do FEHB retirees on Medicare keep this coverage?	We could not confirm a single OPM rule for retirees. Check your carrier’s Medicare-side formulary when you enroll in Medicare
Is the requirement getting stricter?	Yes. OPM’s plan year 2027 call letter says anti-obesity drugs must only be covered when used together with intensive behavioral therapy

OPM’s call letters and carrier benefit terms change year to year. Confirm your specific plan’s current brochure before assuming anything below applies to you.

Want to see what you'd pay without relying on FEHB at all?

Compare Cash-Pay GLP-1 Options →

Where the mandate came from

The OPM Office of Inspector General described the mandate in a December 2025 data brief (2025-CAAG-019): “In January 2023, OPM’s Healthcare and Insurance office issued a Carrier Letter mandating the coverage of at least one GLP-1 by all FEHB Program carriers.” Federal benefits reporting ties plan-level implementation to the 2024 plan year.

OPM repeated and widened the rule in its plan year 2027 call letter (Carrier Letter 2026-07, March 31, 2026). Carriers must keep “at least one anti-obesity medication (AOM) from the GLP-1 class for weight loss and at least two (2) additional oral AOM options” on their formularies.

The newest drug approved for weight management is Foundayo (orforglipron), which Lilly announced the FDA approved on April 1, 2026. We could not confirm its status on FEHB formularies, so if your prescriber is considering it, check your plan’s current formulary directly.

Why “covered” still means very different costs

The mandate sets a floor, not a fixed price. Each FEHB carrier decides its own formulary tier, prior authorization criteria, and cost-sharing for the GLP-1s it covers. Two federal employees with the same prescription on different plans can end up with very different bills.

Coverage of a specific drug also varies by plan option. Before you assume Wegovy or Zepbound is the covered GLP-1 on your plan, check your plan’s current brochure and formulary or call the number on your member ID card. Comparison sites do not always agree with each other on this.

Denied, or stuck on a prior authorization?

Get the Appeal Letter Template →

What prior authorization usually asks for

FEHB plans generally require prior authorization for weight-loss GLP-1s even though the drug class is covered. Your plan’s criteria can differ, but expect requests along these lines:

BMI thresholds. Many plans mirror the populations studied in the drug trials. Wegovy’s label describes trials in adults with a BMI of 30 or higher, or 27 to 29.9 with at least one weight-related condition such as high blood pressure or high cholesterol.
Intensive behavioral therapy. For plan year 2027, OPM’s call letter says anti-obesity drugs “must only be covered when used concurrently with IBT,” and that attestation statements alone are not enough. Expect your plan to ask for proof that you are in a structured lifestyle program before and during treatment.
Periodic reauthorization. Many plans require renewal after a set period. The renewal rules are set by each plan, so ask for them in writing.

Losing coverage mid-year because a reauthorization check wasn’t met is a real risk under plans that build it in.

Diabetes-labeled prescriptions skip most of this. Ozempic, Mounjaro, and similar drugs prescribed for type 2 diabetes are generally covered under standard pharmacy benefits across FEHB plans, without the weight-loss-specific prior authorization hurdles above.

The spending behind the mandate

The same OPM Inspector General brief measured the cost. Looking at two carriers that together cover 69% of FEHB members, annual GLP-1 spending rose from less than $400 million in 2019 to $2.6 billion in 2024, a 554 percent increase. GLP-1s went from 4 percent of total pharmacy spending in that group to 18 percent over the same period. That cost growth helps explain why plans apply prior authorization and reauthorization rules as tightly as they do.

If you’re denied, or the tier makes it unaffordable

Check whether the issue is the drug or the diagnosis. A weight-loss-only prescription facing a denial or high tier placement is a different problem than a diabetes prescription being denied, which would be unusual. Confirm which category your claim falls into before escalating.

Ask your plan for its specific prior authorization criteria in writing, rather than relying on what a coworker’s plan required. Different carriers and even different plan options within the same carrier can set different BMI and program-enrollment requirements.

If the tier cost is the real obstacle, compare it against cash-pay and savings-card options before assuming FEHB coverage is your only route. Our copay card and patient assistance guide and cheapest GLP-1 online guide cover what those alternatives cost, independent of your FEHB plan.

Bottom Line

FEHB coverage of at least one GLP-1 has been required at the program level since January 2023, but that mandate sets a floor, not a fixed benefit. Your actual cost depends on which carrier and plan option you picked, what tier it puts the drug on, and what prior authorization and reauthorization rules apply. From 2027, plans must also tie weight-loss drug coverage to intensive behavioral therapy. Diabetes prescriptions usually have an easier path. Check your specific plan’s current brochure rather than assuming a figure you read elsewhere applies to you.

FAQ

Does FEHB cover Wegovy or Zepbound?

At the program level, yes: every FEHB carrier has been required to cover at least one weight-loss GLP-1 since a January 2023 OPM mandate. Which specific drug, at what tier, and under what prior authorization varies by your specific carrier and plan option, so confirm against your current plan brochure.

Why do federal employees report such different costs for the same drug?

Because the OPM mandate requires coverage of at least one GLP-1, but leaves tier placement, cost-sharing, and prior authorization criteria to each carrier and plan. Two federal employees with the same prescription on different FEHB plans can face very different out-of-pocket costs as a result.

Does FEHB cover Ozempic or Mounjaro for diabetes?

Generally yes, under standard pharmacy benefits, without the weight-loss-specific prior authorization hurdles that apply to a weight-loss-only prescription.

What happens to my FEHB GLP-1 coverage when I retire?

We could not confirm a single OPM rule on how the GLP-1 requirement applies to retirees in a carrier’s Medicare Advantage or Part D plan. Ask your carrier for its Medicare-side formulary when you transition, since Medicare coverage rules differ from active-employee FEHB rules.

Is FEHB coverage getting stricter for GLP-1s?

Yes. OPM’s plan year 2027 call letter says anti-obesity drugs must only be covered when used together with intensive behavioral therapy, and that attestation statements alone are not enough. Your carrier’s approved 2027 brochure will show how your plan applies this.

This guide describes OPM's FEHB GLP-1 coverage mandate and general carrier patterns as of November 2026, based on OPM's Office of Inspector General data brief 2025-CAAG-019 and OPM Carrier Letter 2026-07. It is not a guarantee of coverage for any individual plan or prescription. Confirm your specific plan's current brochure and prior authorization rules with your carrier before making treatment decisions. This is informational only, not medical advice. Full details in our disclaimer.

Guides:

Tools:

Insurance Coverage Checker

Compare: All Providers

What we checked

This AI-assisted public-source desk check reviewed the OPM Inspector General’s December 2025 GLP-1 data brief, OPM’s plan year 2027 call letter, the FDA-approved Wegovy label on DailyMed, and Lilly’s Foundayo approval announcement on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.